Literature DB >> 28533020

The Role of PYY in Pancreatic Islet Physiology and Surgical Control of Diabetes.

Claudia Guida1, Sam Stephen1, Romain Guitton2, Reshma D Ramracheya3.   

Abstract

Bariatric surgery in obese individuals leads to rapid and lasting remission of type 2 diabetes (T2D). This phenomenon occurs independently of weight loss possibly via a combination of factors. The incretin hormone GLP-1 has so far been recognised as a critical factor. However, recent data have indicated that elevation in another gut hormone, peptide tyrosine tyrosine (PYY), may drive the beneficial effects of surgery. Here we discuss recent findings on PYY-mediated control of glucose homeostasis and its role in diabetes, in the context of what is known for GLP-1. Identification of factors that increase the expression of PYY following bariatric surgery and elucidation of its role in diabetes reversal may have clinical relevance as a nonsurgical therapy for T2D.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  bariatric surgery; diabetes; incretins; peptide tyrosine tyrosine (PYY)

Mesh:

Substances:

Year:  2017        PMID: 28533020     DOI: 10.1016/j.tem.2017.04.005

Source DB:  PubMed          Journal:  Trends Endocrinol Metab        ISSN: 1043-2760            Impact factor:   12.015


  11 in total

1.  Theoretical study of the interactions between peptide tyrosine tyrosine [PYY (1-36)], a newly identified modulator in type 2 diabetes pathophysiology, with receptors NPY1R and NPY4R.

Authors:  Yee Siew Choong; Yee Ying Lim; Jia Xin Soong; Nandini Savoo; Claudia Guida; Lydia Rhyman; Reshma Ramracheya; Ponnadurai Ramasami
Journal:  Hormones (Athens)       Date:  2021-03-29       Impact factor: 2.885

2.  SCFAs strongly stimulate PYY production in human enteroendocrine cells.

Authors:  P Larraufie; C Martin-Gallausiaux; N Lapaque; J Dore; F M Gribble; F Reimann; H M Blottiere
Journal:  Sci Rep       Date:  2018-01-08       Impact factor: 4.379

Review 3.  Mechanisms underlying the weight loss effects of RYGB and SG: similar, yet different.

Authors:  A Pucci; R L Batterham
Journal:  J Endocrinol Invest       Date:  2018-05-05       Impact factor: 4.256

Review 4.  Peptides from Natural or Rationally Designed Sources Can Be Used in Overweight, Obesity, and Type 2 Diabetes Therapies.

Authors:  Mayara C F Gewehr; Renata Silverio; José Cesar Rosa-Neto; Fabio S Lira; Patrícia Reckziegel; Emer S Ferro
Journal:  Molecules       Date:  2020-02-29       Impact factor: 4.411

Review 5.  PYY, a Therapeutic Option for Type 2 Diabetes?

Authors:  Claudia Guida; Reshma Ramracheya
Journal:  Clin Med Insights Endocrinol Diabetes       Date:  2020-01-22

6.  Positive Effects of NPY1 Receptor Activation on Islet Structure Are Driven by Pancreatic Alpha- and Beta-Cell Transdifferentiation in Diabetic Mice.

Authors:  Ryan A Lafferty; Neil Tanday; R Charlotte Moffett; Frank Reimann; Fiona M Gribble; Peter R Flatt; Nigel Irwin
Journal:  Front Endocrinol (Lausanne)       Date:  2021-02-25       Impact factor: 5.555

7.  Predictive Model of Type 2 Diabetes Remission after Metabolic Surgery in Chinese Patients.

Authors:  Yufang Luo; Zi Guo; Honghui He; Youbo Yang; Shaoli Zhao; Zhaohui Mo
Journal:  Int J Endocrinol       Date:  2020-10-31       Impact factor: 3.257

8.  Design and Evaluation of Peptide Dual-Agonists of GLP-1 and NPY2 Receptors for Glucoregulation and Weight Loss with Mitigated Nausea and Emesis.

Authors:  Brandon T Milliken; Clinton Elfers; Oleg G Chepurny; Kylie S Chichura; Ian R Sweet; Tito Borner; Matthew R Hayes; Bart C De Jonghe; George G Holz; Christian L Roth; Robert P Doyle
Journal:  J Med Chem       Date:  2021-01-15       Impact factor: 7.446

Review 9.  Effect of Bariatric Surgery on Metabolic Diseases and Underlying Mechanisms.

Authors:  Yu Ji; Hangil Lee; Shawn Kaura; James Yip; Hao Sun; Longfei Guan; Wei Han; Yuchuan Ding
Journal:  Biomolecules       Date:  2021-10-26

Review 10.  Dissecting the Physiology and Pathophysiology of Glucagon-Like Peptide-1.

Authors:  Silvano Paternoster; Marco Falasca
Journal:  Front Endocrinol (Lausanne)       Date:  2018-10-11       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.